Zeneca Limited

Ici Americas, Inc.

Astrazeneca Ab

Imperial Chemical Industries Limited

Nicholas International Limited

Imperial Chemical Company

Thomas Michael Bare

Richard Bruce Sparks

Rebecca Urbanek

James Roy Empfield

Dean Brown

Wenhua Xiao

Megan Murphy

Gary Steelman

Jeffrey Alan McKinney

Timothy W Davenport

Carey Horchler

Frances Marie McLaren

Edward Vacek

Christine Barlaam

Keith John Herzog

Anthony F Heald

Janet Marie Forst

Vernon Alford

Paul F Jackson

Marc Jerome Chapdelaine

Charles D McLaren

John T Suh

Paul Francis Jackson

James B Campbell

Laura Enid Garcia-Davenport

James Franklin Resch

Compounds according to structural diagram (I) The following is an examiner's statement of reasons for allowance: In view of applicants' amendments to the claims which limit 'E' to phenyl or cycloalkyl groups the rejections of the previous action no longer pertain as they at best teach 'E' as alkyl.

1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-diones and their use for the treatment of pain

A compound, 7-chloro-4-hydroxy-2-(2-chloro-4-methylphenyl)-1,2,5,10-tetrahydropyridazino [4,5-b]quinoline-1,10-dione, pharmaceutically-acceptable salts thereof, a method for treating pain comprising administration of a pain-ameliorating effective amount of the compound and pharmaceutical compositions containing the compound.

Compound and method for the treatment of pain

A compound, 7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione, its (&#x2212;) enantiomer, its (+) enantiomer, pharmaceutically-acceptable salts thereof, a method for treating pain comprising administering a pain-ameliorating effective amount of the (&#x2212;) enantiomer to an individual suffering from pain and pharmaceutical compositions containing the (&#x2212;) enantiomer are disclosed.

7-chloro-4-hydroxy-2-(2-pyridylethyl)-1,2,5,10-tetrahydropyridazino[4,5-b]quinoline-1,10-dione and the use thereof for the treatment of pain

Compounds useful for the treatment of pain in accord with structural diagram (I), or tautomers or pharmaceutically-acceptable salts of such compounds, wherein R and A are as disclosed in the specification. Also disclosed are methods for the treatment of pain using compounds according to structural diagram (I) and pharmaceutical compositions comprising compounds according to structural diagram (I).

1, 2, 5, 10-tetrahydropyridazino&lsqb;4, 5-b&rsqb;quinoline-1,10-diones and their use for the treatment of pain

A compound, 7-chloro-4-hydroxy-2-(2-chloro-4-methylphenyl)-1,2,5,10-tetrahydropyridazino&lsqb;4,5-b&rsqb;quinoline-1,10-dione, pharmaceutically-acceptable salts thereof, a method for treating pain comprising administration of a pain-ameliorating effective amount of the compound and pharmaceutical compositions containing the compound.

Alpha-substituted pyridazino quinoline compounds

Compounds and methods for the treatment of pain

The present invention relates to compounds, pharmaceutical compositions and methods of using compounds having the formula below

Pyridazino quinoline compounds

The invention relates to pyridazinoquinoline compounds of the formulas B and B&prime;

The present invention concerns compounds according to the following formula, ##STR1## wherein: R.sup.1 is (CH.sub.2).sub.n,L where n is an integer in the range 0 to 6, and L is a carbon-linked five-membered heteroaryl ring having an oxygen or sulfur heteroatom, R.sup.4 is hydrogen, halo or NO.sub.2, and pharmaceutical compositions and methods of using thereof in the treatment and/or prevention of neurological diseases or conditions.

Heteroaryl-substituted pyridazino quinoline compounds

The invention relates to alpha-substituted pyridazino-quinoline compounds of the formula I: ##STR1## wherein Ring A is chosen from an ortho fused aromatic or heteroaromatic five- or six-membered ring; R.sup.1 is selected from a variety of substituents including halogen, (1-4C)alkyl and nitro; R.sup.2 is selected from a group of the formula R2', R2' or R2'' wherein R2' is --CHR.sup.3 (CH.sub.2).sub.n C(O)NR.sup.5 R.sup.6 ; R2' is --CHR.sup.3 (CH.sub.2).sub.n R.sup.4 and R2'' is --CHR.sup.3 (CH.sub.2).sub.n L wherein n is 0-6; R.sup.5 is aryl or substituted aryl; R.sup.6 is (1-6C)alkyl or hydrogen; R.sup.3 is (1-6C)alkyl, (0-6C)alkylCF.sub.3 or (0-6C)alkylCOOR'; R.sup.4 is (1-6C)alkyl, (2-6C)alkyl containing a double or triple bond, or (0-6C)alkylaryl; L is a variety of substituents including phenyl, heteroaryl and CO.sub.2 R'; R' is hydrogen or (1-4C)alkyl; Z is selected from oxo, --OH, H,H--, H, (1-6C)alkyl or (1-6C)alkylaryl; and R.sup.7 is hydrogen or --(CO)R.sup.8 wherein R.sup.8 is a variety of substituents including hydrogen and (1-12C) alkyl.

Pyridazion quinoline compounds

The present invention relates to pyridazino�4,5-b!quinolines, and pharmaceutically useful salts thereof, which are excitatory amino acid antagonists and which are useful when such antagonism is desired such as in the treatment of neurological disorders. The invention further provides pharmaceutical compositions containing pyridazino�4,5-b!quinolines as active ingredient, and methods for the treatment of neurological disorders.

Pyridazinedione compounds useful in treating neurological disorders

Pyridazinedione compounds useful in the treating neurological disorders

The present invention relates to pyridazino[4,5-b]indoles, and pharmaceutically useful salts thereof, which are excitatory amino acid antagonists and which are useful when such antagonism is desired such as in the treatment of neurological disorders. The invention further provides pharmaceutical compositions containing pyridazino[4,5-b]indoles as active ingredient, and methods for the treatment of neurological disorders.

Pyridazinedione derivatives useful in treatment of neurological disorders

Growing community of inventors

West Chester, PA, United States of America

Thomas Michael Bare